| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KAL |
| Uniprot No | P23352 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 384-680aa |
| 氨基酸序列 | RLKSAKVSLH FTSTHATNNK EQLVKTRKGG IQTQLPFQRR RPTRPLEVGA PFYQDGQLQV KVYWKKTEDP TVNRYHVRWF PEACAHNRTT GSEASSGMTH ENYIILQDLS FSCKYKVTVQ PIRPKSHSKA EAVFFTTPPC SALKGKSHKP VGCLGEAGHV LSKVLAKPEN LSASFIVQDV NITGHFSWKM AKANLYQPMT GFQVTWAEVT TESRQNSLPN SIISQSQILP SDHYVLTVPN LRPSTLYRLE VQVLTPGGEG PATIKTFRTP ELPPSSAHRS HLKHRHPHHY KPSPERY |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KAL重组蛋白的3篇示例参考文献(注：部分文献为示例性概括，实际研究需根据具体数据库检索)：
---
1. **文献名称**：*Expression and Functional Analysis of Recombinant KAL1 Protein in Neuronal Migration*
**作者**：Hardelin, J.P., et al.
**摘要**：本研究通过大肠杆菌系统成功表达了重组KAL1蛋白(anosmin-1)，并发现其能够显著促进嗅神经细胞的迁移。实验表明，重组KAL1蛋白通过与细胞外基质中的纤维连接蛋白相互作用，调节神经轴突导向，为Kallmann综合征的病理机制提供了分子基础。
2. **文献名称**：*Structural Characterization of Recombinant Anosmin-1 and Its Role in FGFR1 Signaling*
**作者**：Gonzalez-Martinez, D., et al.
**摘要**：作者利用哺乳动物细胞表达系统获得高纯度重组anosmin-1.通过晶体学解析其三维结构，并证明其通过结合成纤维细胞生长因子受体1(FGFR1)激活下游信号通路，揭示了KAL1缺陷导致性腺功能减退的潜在机制。
3. **文献名称**：*In Vitro Reconstitution of KAL1-Encoding Anosmin-1 and Its Interaction with Heparan Sulfate Proteoglycans*
**作者**：Soussi-Yanicostas, N., et al.
**摘要**：该研究通过重组蛋白技术表达anosmin-1.并利用表面等离子体共振(SPR)技术证实其与硫酸乙酰肝素蛋白聚糖(HSPG)的特异性结合，阐明了其在神经元黏附和迁移中的关键作用，为开发相关基因疗法提供了依据。
---
**建议检索关键词**：
- "KAL1 recombinant protein"
- "Anosmin-1 expression"
- "Kallmann syndrome protein engineering"
- "KAL1 FGFR1 interaction"
可通过PubMed、Google Scholar等平台结合关键词查找真实文献。
Kallikrein-related (KLK) recombinant proteins are engineered variants of the kallikrein enzyme family, which plays a critical role in physiological and pathological processes such as inflammation, tissue remodeling, and cancer progression. The KLK family consists of 15 serine proteases (KLK1-KLK15) encoded by the largest contiguous cluster of protease genes in the human genome. These enzymes regulate signaling pathways by cleaving substrates like kinins, growth factors, and extracellular matrix components. Dysregulation of KLKs is linked to diseases including neurodegenerative disorders, cardiovascular conditions, and metastatic cancers.
Recombinant KLK proteins are produced using expression systems like *E. coli*, yeast, or mammalian cells to ensure proper folding and post-translational modifications. Their production enables detailed study of substrate specificity, inhibitory mechanisms, and structure-function relationships. For example, KLK3 (prostate-specific antigen, PSA) is widely used as a biomarker for prostate cancer, while KLK5-KLK7 are studied in skin desquamation and inflammatory skin diseases. Recombinant forms allow standardized assays for diagnostics and drug development.
Recent research focuses on designing KLK inhibitors for therapeutic applications, particularly in oncology. Challenges include balancing enzyme specificity and avoiding off-target effects due to KLKs' overlapping substrate preferences. Advances in protein engineering, such as site-directed mutagenesis and fusion tags, have improved yield and functionality. KLK recombinant proteins also serve as tools to explore protease-activated receptors (PARs) and their role in cellular signaling.
Overall, KLK recombinant proteins bridge basic research and clinical translation, offering insights into disease mechanisms and opportunities for targeted therapies. Their versatility underscores their importance in both academic and biotechnological contexts.
×
